Solasia Pharma K.K. revised earnings guidance for the fiscal year ending December 31, 2021. For the period, the company expected Revenue of JPY 600 million against JPY 1,600 million to JPY 2,600 million expected earlier. Operating loss of JPY 2,500 million against JPY 2,800 million to JPY 1,800 million expected earlier. Loss attributable to owners of parent of JPY 2,500 million against JPY 2,800 million to JPY 1,800 million. Basic loss per share of JPY 18.73 million against JPY 22.83 to 14.68 per share expected earlier.